Cart
sales@molnova.com
Cetuximab (anti-EGFR)
CAS No. 205923-56-4
Cetuximab (anti-EGFR)( C225 )
Catalog No. M21142 CAS No. 205923-56-4
Cetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 275 | In Stock |
|
| 5MG | 458 | In Stock |
|
| 10MG | 662 | In Stock |
|
| 25MG | 1036 | In Stock |
|
| 50MG | 1367 | In Stock |
|
| 100MG | 1841 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCetuximab (anti-EGFR)
-
NoteResearch use only, not for human use.
-
Brief DescriptionCetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
-
DescriptionCetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
-
In Vitro——
-
In Vivo——
-
SynonymsC225
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Areacancer
-
IndicationColorectal Cancer
Chemical Information
-
CAS Number205923-56-4
-
Formula Weight2756.23
-
Molecular FormulaC107H179N35O36S7
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Huang S M Bock J M Harari P M . Epidermal Growth Factor Receptor Blockade with C225 Modulates Proliferation Apoptosis and Radiosensitivity in Squamous Cell Carcinomas of the Head and Neck1[J]. Cancer Res 1999 59(8):1935-1940.
molnova catalog
related products
-
PD153035 hydrochlori...
PD153035 hydrochloride (ZM 252868; AG 1517) is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM; little effect against PGDFR, FGFR, CSF-1, InsR and Src.
-
AZD-9291
A potent, selective, third-generation irreversible inhibitor of mutant EGFR with IC50s of 1/12/5 nM for L858R-T790M/L858R/L861Q respectively.
-
CO-1686
A potent, highly selective, irreversible inhibitor of mutant EGFR with Ki of 21.5 nM for EGFR L858R/T790M.
